1. Eculizumab salvage therapy for delayed hemolysis transfusion reaction in sickle cell disease patients
by Guillaume Dumas, Anoosha Habibi, Thierry Onimus, Jean-Claude Merle, Keyvan Razazi, Armand Mekontso Dessap, Frederic Galactéros, Marc Michel, Veronique Frémeaux Bacchi, France Noizat Pirenne, and Pablo Bartolucci
Blood
Volume 127(8):
February 25, 2016
©2016 by American Society of Hematology

2. Event history and response to treatment in 3 patients with delayed hemolytic transfusion reaction.
Event history and response to treatment in 3 patients with delayed hemolytic transfusion reaction. Day 0 indicates the day of the transfusion responsible for the hemolytic episode. (A) Timeline history of patient 1. (B) Timeline history of patient 2. (C) Timeline history of patient 3. Blue arrows represent eculizumab infusion. Black arrows indicate recombinant erythropoietin injections (EPO). Red arrows indicate RBC transfusion days; green arrows represent plasma exchange sessions. HbA (indicated as a percentage of total Hb concentration); reticulocytes ([retics] normal range, 20 × 109/L-100 × 109/L); lactate dehydrogenase ([LDH] normal range, U/L).
Guillaume Dumas et al. Blood 2016;127:
©2016 by American Society of Hematology